Avanzanite Bioscience Secures €32 Million Series A Investment from MVM Partners
Adam Plich, Founder and CEO, Avanzanite • Avanzanite
AMSTERDAM, November 19, 2025 (WELLNESS INTERVIEWS) — Specialty pharmaceutical company Avanzanite Bioscience, a European firm focused on rare disease medicines, has secured a €32 million Series A investment from global life-science private equity firm MVM Partners.
Wellness Interviews
♾️
Wellness Interviews ♾️
The funding marks MVM’s first institutional investment in Avanzanite and will be used to expand the company’s commercial infrastructure across all 32 European markets, support the launch of current and future rare disease products, and pursue additional strategic alliances and asset acquisitions.
Jack Tanaka, MVM Partner • Photo Credit: Avanzanite
The announcement follows what the company reports as a record Q3 2025, with revenue tripling year-on-year and rising more than 20% compared to the previous quarter. Avanzanite currently operates three strategic alliances and three rare disease product launches across nephrology, ophthalmology, and haematology.
“Avanzanite's experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe,” said Jack Tanaka, Partner at MVM.
“We are truly honoured to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital – it demonstrates conviction in our mission and belief in the ‘Champions League’ team that powers Avanzanite. With MVM’s support we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances – setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we’ve come, it is just the beginning of our journey,” said Adam Plich, Founder and CEO of Avanzanite.
MVM will invest up to €32 million from its €500 million sixth fund and has allocated additional capital for future growth initiatives. The firm has also joined Avanzanite’s Board of Directors.
Avanzanite, founded in 2022 and headquartered in Amsterdam, operates a fully integrated model that combines commercial capabilities, scientific expertise, and market access functions to bring orphan medicines to patients across Europe—areas where traditional commercialization approaches often face barriers.
For more information, visit www.avanzanite.com.
Source: Avanzanite Bioscience B.V.
